This platform technology can provide a safer, more reliable way for patients to receive haemodialysis or bypass arterial blockages. Worldwide, these unmet clinical needs represent a £4.2 billion yearly available market


Enables safe needle crossing and guidewire placement across vessels

A chronic total occlusion (CTO) is the most severe stage of the disease - a complete arterial blockage that risks limb loss.


[London, UK – Nov 17th 2025] – Pathfinder Medical, a pioneer in minimally invasive vascular access technologies, is pleased to announce the appointment of Dr. Lorenzo Patrone as its Chief Medical Officer (CMO).